From theory to reality: the quest for autophagy boosting drugs

From theory to reality: the quest for autophagy boosting drugs

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Peter Hamley, Chief Scientific Officer of Samsara Therapeutics, on understanding and leveraging the body’s cellular recycling process – autophagy.

Autophagy biology has emerged as a ray of hope in addressing age-related diseases such as neurodegenerative disorders. Substantial effort in academia has been directed at advancing our understanding of the field and paving the way for ground-breaking therapies. But with genuine challenges in harnessing the power of autophagy and in developing effective therapies in this disease area, how close are we to really finding the first autophagy boosting drugs…?

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2391

Samsara Therapeutics

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Samsara Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule autophagy activators to address age-related neurodegenerative diseases. The company targets fundamental mechanisms of cellular aging through compounds designed to enhance autophagy, a cellular cleanup process critical for removing damaged proteins and organelles. Samsara's pipeline includes programs for amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Charcot-Marie-Tooth disease type 1A, with the goal of providing disease-modifying treatments that address root causes rather than symptoms. Operating from headquarters in Boston and an R&D hub in Oxford, the company aims to establish autophagy-inducing therapeutics as a new class of geroprotective agents.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Guest Contributor

A guest contributor joins us to add to the longevity conversation!

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE